Pyrotinib: all 113 studies that test it
Page 1 of 2. Open to participants first (55), then studies with results posted, then the rest; newest registration first within each.
- Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast CancerNot yet recruitingNCT07892274Phase 3
- A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXdNot yet recruitingNCT07836257Phase 2
- Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBCRecruitingNCT07797218Phase 3
- Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast CancerNot yet recruitingNCT07766772Phase 2
- Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab FailureRecruitingNCT07708194Phase 1/2
- Precision Medicine for Immunotherapy-Resistant Advanced Esophageal CancerNot yet recruitingNCT07653451Phase 2/3
- Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast CancerRecruitingNCT07615751Phase 3
- Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast CancerRecruitingNCT07600164Phase 4
- Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted TherapyRecruitingNCT07528716Phase 3
- Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast CancerRecruitingNCT07393425Phase 2
- Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast CancerRecruitingNCT07340398Phase 2
- ctDNA in HER2+ EBC Neoadjuvant TreatmentRecruitingNCT07335081Phase 2
- Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast CancerRecruitingNCT07180082Phase 2
- Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II StudyNot yet recruitingNCT07179939Phase 2
- SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast CancerNot yet recruitingNCT07132242Phase 2
- RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II StudyRecruitingNCT07065435Phase 2
- A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System TumorsNot yet recruitingNCT07053150Phase 2
- Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast CancerNot yet recruitingNCT07019337Phase 2
- The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical StudyRecruitingNCT06958627Phase 2/3
- Pyrotinib in HER2-positive Early Breast CancerNot yet recruitingNCT06718335Not applicable
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingNCT06692491Phase 2
- Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06684600Phase 2
- Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.RecruitingNCT06563999Phase 2
- The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 PositiveNot yet recruitingNCT06495541Not applicable
- Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCsNot yet recruitingNCT06475443Phase 2
- Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical TrialRecruitingNCT06278870Phase 3
- A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast CancerRecruitingNCT06234137Not applicable
- The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).RecruitingNCT06217185Phase 4
- Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain MetastasesRecruitingNCT06152822Phase 2
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingNCT06145308Phase 2
- Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast CancerRecruitingNCT06035679Not applicable
- Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast CancerRecruitingNCT05910398Phase 3
- Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast CancerRecruitingNCT05880927Phase 2
- Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast CancerRecruitingNCT05861271Phase 2
- Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast CancerNot yet recruitingNCT05841381Phase 3
- Pyrotinib in Women With High-risk in Early Stage Breast CancerRecruitingNCT05834764Phase 2
- Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast CancerRecruitingNCT05823623Phase 2
- Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI TherapyNot yet recruitingNCT05806671Phase 2
- Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung CancerRecruitingNCT05751018Phase 2
- A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 MutationNot yet recruitingNCT05745740Phase 1/2
- Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast CancerRecruitingNCT05659056Phase 2
- Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast CancerRecruitingNCT05638594Phase 2
- A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer PatientsRecruitingNCT05635487Phase 2
- A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast CancerNot yet recruitingNCT05621434Phase 2
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingNCT05582499Phase 2
- Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)Not yet recruitingNCT05577923Phase 2
- GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast CancerRecruitingNCT05575804Phase 1/2
- A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung CancerRecruitingNCT05482568Phase 1/2
- Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast CancerRecruitingNCT05292742Phase 2
- Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant TherapyNot yet recruitingNCT04973319Phase 3
- Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast CancerNot yet recruitingNCT04900311Phase 2
- Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast CancerNot yet recruitingNCT04858516Phase 2
- PLATFORM Study of Precision Medicine for Rare TumorsRecruitingNCT04423185Phase 2
- Adjuvant Study of Pyrotinib in HER-2 Positive Breast CancerRecruitingNCT04254263Phase 3
- Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast CancerNot yet recruitingNCT04158856Phase 2
- Neoadjuvant Inetetamab and Pyrotinib and Nab-paclitaxel for HER2+Breast CancerCompletedNCT05444998Phase 2
- Precise Therapy for Refractory HER2 Positive Advanced Breast CancerStatus unknownNCT05429684Phase 3
- Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038Status unknownNCT05429294Phase 2
- Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast CancerStatus unknownNCT05255523Phase 2
- Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy SubjectsCompletedNCT05252546Phase 1
- Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaStatus unknownNCT05111444Phase 2
- Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast CancerStatus unknownNCT05076695Phase 2
- Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric CancerStatus unknownNCT05070598Phase 2
- Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and PyrotinibStatus unknownNCT05020964Phase 2
- Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast CancerActive, not recruitingNCT04872985Phase 2
- Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast CancerStatus unknownNCT04717531Phase 2
- Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast CancerStatus unknownNCT04681911Phase 2
- Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast CancerStatus unknownNCT04605575Phase 2
- A Trial of SHR1258 in Patients With Biliary Tract CancerWithdrawnNCT04571710Phase 2
- Effect of Itraconazole on the Pharmacokinetics of Pyrotinib in Healthy SubjectsCompletedNCT04479891Phase 1
- Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based ChemotherapyCompletedNCT04447118Phase 3
- Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast CancerActive, not recruitingNCT04398914Phase 2
- An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.Active, not recruitingNCT04395989Phase 2
- A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal CancerStatus unknownNCT04380012Phase 2
- Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast CancerCompletedNCT04367090Phase 1
- Molecularly Targeted Umbrella Study in Luminal Advanced Breast CancerStatus unknownNCT04355858Phase 2
- Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in ChinaStatus unknownNCT04334330Phase 2
- Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast CancerStatus unknownNCT04293276Phase 2
- Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast CancerActive, not recruitingNCT04290793Phase 2/3
- Pyrotinib in Breast Cancer Patients With Poor Response to the Neoadjuvant Treatment of Trastuzumab and PertuzumabStatus unknownNCT04255056Phase 2
- Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast CancerStatus unknownNCT04246502Phase 2
- A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.Status unknownNCT04236310Phase 2
- The Basket Study of Pyrotinib Maleate for HER2-Postive Solid TumorStatus unknownNCT04179656Phase 2
- Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast CancerActive, not recruitingNCT04126525Phase 2
- Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast CancerStatus unknownNCT04088110Phase 2
- Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast CancerTerminatedNCT04066790Phase 2
- Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion MutationStatus unknownNCT04063462Phase 2
- Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )Status unknownNCT04033172Phase 2
- A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast CancerStatus unknownNCT03997539Phase 2
- A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast CancerActive, not recruitingNCT03980054Phase 3
- Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.Status unknownNCT03947242Not applicable
- A Study of Pyrotinib Plus Vinorelbine in Patients With Brain Metastases From HER2-positive Metastatic Breast CancerStatus unknownNCT03933982Phase 2
- Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast CancerStatus unknownNCT03923179Phase 2
- Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast CancerStatus unknownNCT03923166Phase 2
- Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBCStatus unknownNCT03910712Phase 2
- A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast CancerStatus unknownNCT03863223Phase 3
- Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast CancerStatus unknownNCT03847818Not applicable
- Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.Status unknownNCT03843749Not applicable
- FUSCC Refractory TNBC Umbrella (FUTURE)Status unknownNCT03805399Phase 1/2
- Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast CancerActive, not recruitingNCT03772353Phase 1/2